Moderna has something exciting for covid vaccine enthusiasts to put on the table these days. Check out the latest reports revealed by CNBC below.
It’s been just revealed that Moderna has reached a memorandum of understanding with Kenya to build a Covid vaccine manufacturing plant in the East African nation, the company announced Monday.
CNBC noted the following:
“Moderna plans to invest $500 million to produce messenger RNA, the technology underlying its Covid vaccines, at the facility with the goal of manufacturing 500 million doses annually. Moderna could fill Covid vaccine doses at the Kenya facility as early as 2023 subject to demand, according to the company.”
It’s also important to mention the fact that Moderna reached the agreement with the support of the U.S. government. As the coronavirus pandemic eases in the U.S., the Biden administration has made increasing vaccination globally a central priority.
Check out the complete article in order to learn more details about this.
Moderna works on a covid booster
Reuters press agency noted that there is an Omicron-specific booster that could be ready by August, the CEO of U.S. biotech firm Moderna told Reuters.
It’s important to note that the company is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing vaccine.
“Last month Moderna began clinical trials for a booster dose specifically designed to target Omicron but initial results from studies in monkeys show the Omicron-specific shot may not offer stronger protection than a new dose of the existing vaccine.”
Moderna chief executive Stephane Bancel said the following:
“We believe a booster will be needed. I don’t know yet if it is going to be the existing vaccine, Omicron-only, or bivalent: Omicron and existing vaccine, two mRNA in one dose.”
Stay tuned for more news about the latest on coronavirus.